Clinical Safety

Beyond the Label: A Clinician's Risk-Benefit Framework for Azithromycin in COPD, Cystic Fibrosis, and Diffuse Panbronchiolitis

Off-label prescribing of azithromycin is common in pulmonary medicine, particularly for chronic inflammatory conditions where the antibiotic's immunomodulatory properties may offer benefit independent of its antimicrobial activity. However, the evidentiary foundation varies considerably across indications, and clinicians face real uncertainty when weighing potential benefit against resistance promotion, adverse effects, and medicolegal exposure. This article offers a structured framework for nav

Sep 12, 2026

Polypharmacy Meets Azithromycin: Navigating Drug Interactions That Clinicians Too Often Miss

Azithromycin's reputation as a well-tolerated antibiotic can obscure its capacity to generate serious adverse drug interactions in patients managing multiple chronic conditions. From antiretrovirals to antiarrhythmics, the drug's interaction profile deserves far more clinical scrutiny than it typically receives at the point of prescribing. This article examines the most clinically significant interactions, illustrates their real-world consequences, and outlines practical strategies for safer pre

Sep 12, 2026

Azithromycin in Pediatric Practice: Navigating Evidence-Based Indications Without Contributing to Overuse

Azithromycin occupies a uniquely contested position in pediatric medicine—genuinely life-saving in certain clinical scenarios, yet among the most frequently overprescribed antibiotics in children across the United States. This practical clinical review examines age-specific dosing parameters, pediatric safety signals including gastrointestinal effects and arrhythmia risk, the evidence base for appropriate indications, and strategies for communicating antibiotic rationale to parents navigating co

Sep 11, 2026

Cardiac Risk and Azithromycin: How Clinicians Should Navigate QT Prolongation in 2024

Azithromycin's association with QT prolongation has generated significant debate since a landmark 2012 FDA Drug Safety Communication brought the issue into sharp focus. More than a decade later, prescribers still face uncertainty about which patients face genuine cardiac risk and how to make evidence-based decisions at the point of care. This guide synthesizes the latest evidence, updated regulatory guidance, and practical risk stratification tools to help US clinicians prescribe with greater co

Sep 11, 2026